Aradigm Corp.

Aradigm Corp.

Aradigm Corp.

Overview
Date Founded

1991

Headquarters

3929 Point Eden Way, Hayward, CA, 94545, USA

Type of Company

Public

Employees (Worldwide)

11 - 50

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology
Medical Products & Equipment

Company Description

Aradigm Corp. operates as a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. Its technologies include diabetes and pain management, AERx essence devices. The company was founded in 1991 and is headquartered in Hayward, CA.

Contact Data
Trying to get in touch with decision makers at Aradigm Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman, President & Chief Executive Officer, Director

Director-Systems Engineering

Director

Coordinator

QA QC Director

Responsible for the Manufacturing Scale

Paths to Aradigm Corp.
Potential Connections via
Relationship Science
You
Aradigm Corp.
Recent Transactions
Details Hidden

Aradigm Corp. raised money in a private placement transaction

Details Hidden

Aradigm Corp. raised money in a private placement transaction

Details Hidden

Aradigm Corp. issued USD Common Stock

Transaction Advisors
Underwriter

Advised onAradigm Corp. issued USD Common Stock

Underwriter

Advised onAradigm Corp. issued USD Common Stock

Investment Advisor

Advised onAradigm Corp. raised money in a private placement transaction

Advisors & Consultants
Legal Advisor

Partner at Jones Day

Legal Advisor

Partner at Morrison & Foerster LLP

Clients

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

The Government of the United States of America is the federal government of the republic of fifty states that constitute the United States, as well as one capital district, and several other territories. The federal government is composed of three distinct branches: legislative, executive and judicial, whose powers are vested by the U.S. Constitution in the Congress, the President, and the federal courts, including the Supreme Court, respectively.

Key Stats and Financials As of
Market Capitalization
$761K
Total Enterprise Value
Earnings Per Share
Suppliers
Grifols SA Biotechnology | Barcelona, Spain

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Competitors
Gilead Sciences, Inc. Biotechnology - Foster City, CA

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

Horizon Therapeutics Plc Pharmaceuticals - Dublin, Ireland

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Insmed, Inc. Wholesale: Consumer Non-Durables/Sundries - Bridgewater, NJ

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Aradigm Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Aradigm Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Aradigm Corp..